CRTC1 and renal cell adenocarcinoma: This is consistent with efficacy reported in other phase 1/2 studies of dual TORC1/2 kinase inhibitors in patients with advanced malignancies,25,27–29 and the ORR of 22% reported in patients with RCC naïve to a TORC1 inhibitor compares favourably to ORRs observed with rapalogs in patients with RCC (ORR 8.6% with temsirolimus8 and 1–5% with everolimus).9,7,30,31 However, a recent Phase 2 study of sapanisertib 30 mg QW versus everolimus 10 mg QD in patients with refractory clear-cell RCC reported no responses with single-agent sapanisertib versus an ORR of 13% with everolimus (NCT02724020).32